Baidu
map

辟谣:低密度脂蛋白升高必须吃药吗?医生表示不同人不一样!

2020-09-26 39健康网 39健康网

低密度脂蛋白就像一辆载满货物的大货车,在路上行驶时,难免会洒落一些胆固醇,沉积在血管壁上,造成心血管疾病风险

蛋白的种类不少,且有好坏之分,今天NA姐要和大家说的就是坏蛋白——低密度脂蛋白。平时我们常说的胆固醇过高,其实就是它里面的低密度脂蛋白在作怪,坏蛋白一旦超标,对身体百害而无一利。

低密度脂蛋白是血脂检查中的一个项目,能搭载几千个胆固醇,负责将血液里的胆固醇运送到身体的各细胞。

简单来说,低密度脂蛋白就像一辆载满货物的大货车,在路上行驶时,难免会洒落一些胆固醇,沉积在血管壁上,造成心血管疾病风险。所以,低密度胆固醇也被称为“坏胆固醇”。

一般来说,普通人的低密度胆固醇的正常标准为≤3.10mmol /L(120mg/dl),3.13-3.59 mmol/L (121-139 mg/dl)为边缘升高,≥3.62 mmol/l(140 mg /dl)为升高。

不过,低密度脂蛋白在正常标准以下,也不一定意味着达标。不同的疾病、不同的人群、不同的原因,低密度脂蛋白的达标标准也不尽相同。

低密度脂蛋白升高是因为吃肉?

可以说,低密度脂蛋白是形成心脑血管疾病的罪魁祸首。有人认为,是吃肉导致低密度脂蛋白升高,因此饮食上改成吃素,却没有把这个指标降下来。那么,引起低密度脂蛋白升高的原因有哪些呢?

遗传:血液中低密度脂蛋白量的生成和代谢几乎是一样的,部分人由于基因的原因,代谢较差,会增加低密度脂蛋白的合成。

肥胖:肥胖的人体内脂肪多,血液中饱和脂肪酸的含量高于正常人,也有低密度脂蛋白过高的风险。

饮食不健康:高热量、高脂肪饮食,经常是煎炸烧烤食物、油腻食物等,就会导致血液中的胆固醇水平增加,使低密度脂蛋白胆固醇指数偏高。

生活不规律:通宵熬夜、暴饮暴食、情绪抑郁、工作压力大等,容易造成内分泌紊乱,增加体内饱和脂肪酸的含量,引起低密度脂蛋白偏高。

因此,低密度脂蛋白升高不仅仅是因为吃肉,不良的生活方式、情绪等因素也同样会导致低密度脂蛋白的升高。

哪些食物可以降低低密度脂蛋白?

有的人体检发现自己低密度脂蛋白偏高,又听说这个指标过高容易引起心血管疾病,就追着医生给自己开药。

事实上,如果低密度脂蛋白<4.9 mmol/L,而且没有吸烟、喝酒等不良嗜好,也没有家族史、糖尿病史等,暂时可以不用服用他汀类药物,调整生活方式和饮食习惯,长期监测即可。

虽然大部分低密度脂蛋白偏高是我自身遗传基因导致的,但是,如果饮食上再胡吃海塞、乱吃一通,那么低密度脂蛋白就会更高。

所以,对于低密度脂蛋白偏高的人来说,适当吃以下这些食物,有助于降低低密度脂蛋白。

1、麦豆。麦豆含有叶酸、维生素B6、类胡萝卜素等营养物质,有助于降低胆固醇,预防血栓

2、海带。海带富含牛磺酸、食物纤维褐藻酸,可以抑制胆固醇的吸收,促进胆固醇分解。

3、胡萝卜。胡萝卜富含果胶酸钙,与胆汁发生化学反应后排出体外,能够有效降低血液中的胆固醇水平。

4、菌菇类。很多菌菇类食物中含有丰富的水溶性纤维,可以帮助降低胆固醇,预防心脑血管疾病。

当然,除了要养成健康的饮食习惯,要想降低低密度脂蛋白,还需要保持合理的体重,加强运动,建议每天花30分钟进行散步、慢跑、爬山、骑自行车、游泳、太极拳等锻炼。

此外,还要戒烟限酒,规律作息,少熬夜,保证充足的睡眠。只有机体免疫力高了,新陈代谢才能好,血管才能更加健康。

无论如何,养成健康的生活方式是预防疾病的基石。如果体检发现自己低密度脂蛋白过高,你知道应该怎么做了吗?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2021-09-11 ms2000001497300385

    谢谢!学习了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2021-01-12 12460f22m82暂无昵称

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2021-06-08 feather87
  4. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-09-30 咻凡

    考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-09-30 jasonlwhuang

    非常棒的分享 如果有哪些基因备查就更好了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-09-27 466906000_35880212

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1016484, encodeId=5f1210164845a, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd95564168, createdName=ms2000001497300385, createdTime=Sat Sep 11 08:33:09 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915805, encodeId=5b9291580507, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:46:36 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679596, encodeId=b23616e9596fb, content=<a href='/topic/show?id=7c549386054' target=_blank style='color:#2F92EE;'>#辟谣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93860, encryptionId=7c549386054, topicName=辟谣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf127794231, createdName=feather87, createdTime=Tue Jun 08 23:39:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889450, encodeId=6ad688945016, content=考虑到非标准化的疾病标准,应考虑进一步设计良好的前瞻性试验以证实这些结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Sep 30 17:00:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889320, encodeId=b0ce8893209e, content=非常棒的分享 如果有哪些基因备查就更好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/b0c7657b625b458eabd6d8c4561c8dc1/161b78d3dd26470fae17fd67e4916c16.jpg, createdBy=cb3d2980997, createdName=jasonlwhuang, createdTime=Wed Sep 30 05:43:30 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424786, encodeId=fb861424e86b3, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Mon Sep 28 11:39:30 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888750, encodeId=1ebc888e507d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb42416426, createdName=466906000_35880212, createdTime=Sun Sep 27 15:28:06 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888624, encodeId=0a7688862496, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbcf5419428, createdName=ms7000001304165217, createdTime=Sun Sep 27 00:46:35 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-09-27 ms7000001304165217

    学习了

    0

相关资讯

Eur Heart J:Alirocumab 对高龄冠心病患者预后的影响研究

降低低密度脂蛋白胆固醇(LDL-C)可降低心血管风险,而与年龄无关,但对老年患者来说,这一证据并不那么有力。

2020 EAS共识声明:低密度脂蛋白导致的动脉粥样硬化性心血管疾病的病理生理学、遗传学和治疗见解

2020年2月,欧洲动脉硬化学会(EAS)发布了低密度脂蛋白导致的动脉粥样硬化性心血管疾病的病理生理学、遗传学和治疗见解声明,本文是第二个讨论低密度脂蛋白和动脉粥样硬化性心血管疾病关系的共识声明。

Circulation:微囊蛋白1(Cav1)通过抑制低密度脂蛋白转运和内皮细胞炎症发挥抗动脉粥样硬化作用

动脉粥样硬化是由病理、生理、炎症和脂质代谢因子协同作用导致的。研究表明,高脂血症小鼠缺失微囊蛋白1(Cav1)/质膜微囊会强烈抑制动脉粥样硬化,这归因为内皮NO合酶(eNOS)激活、NO生成增加以及炎症和低密度脂蛋白转运减少。但eNOS激活和NO产生在Cav1动脉粥样硬化中的保护作用以及Cav1/质膜微囊控制饮食诱导的动脉粥样硬化的分子机制尚不清楚。研究人员建立了eNOS、Cav1和Ldlr三敲除

J Nutr:每天一个牛油果,“坏胆固醇”远离我!

近期,美国宾夕法尼亚大学研究人员发表的一项随机对照研究提示,对于超重和肥胖的人来说,每天吃一个牛油果,有助于降低“坏胆固醇”水平。

Curr Atheroscle Rep:从机制到实践,PCSK9抑制剂成为降脂治疗新选择

PCSK9是一种全新的低密度脂蛋白调节靶向物质,主要通过调节肝脏LDL受体(LDLR)的表达和分泌活性来发挥作用。现有研究已证实,个体PCSK9水平不仅是罕见的先天性LDL-C调控物质,更可以作为降低动脉粥样硬化性脂蛋白水平和心血管风险的新型药物靶点。Current Atherosclerosis Reports杂志近期发表了一项综述,汇总最新的相关临床研究成果,将其结论整合为临床亚组结论和新治疗

JACC:低密度脂蛋白胆固醇可预测外周动脉疾病风险

低密度脂蛋白胆固醇(LDL-C)与冠心病的发生风险相关,但其与外周血管疾病的相关性尚不清楚。本研究的目的旨在评估LDL-C水平是否与视网膜病变、神经病变、慢性肾脏疾病(CKD)和外周动脉疾病(PAD)相关。 研究发现,高水平的LDL-C与视网膜病变和神经病变无明显相关性,而CKD和PAD与LDL-C水平呈逐步相关性(p<<0.001)。LDL-C每升高1mmol/L,视网膜病变的

Baidu
map
Baidu
map
Baidu
map